National Foundation for Cancer Research shared a post on LinkedIn:
“Promising results from Yiviva’s Phase 2b trial!
Presented at both ASCO25 and ESMOGI25, YIV-906 combined with sorafenib significantly improved survival outcomes for patients with advanced hepatocellular carcinoma and chronic hepatitis B.
Patients in the YIV-906 arm saw:
- Median overall survival nearly doubled
- Improved time to tumor progression
- Better treatment tolerance
Backed by NFCR, AFCR, Yale, and others, YIV-906 represents a novel systems biology-based approach to enhancing cancer therapies.”
More post featuring NFCR on OncoDaily.